AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it ...